Skip to content

Canagliflozin

Also called Invokana / SGLT2 inhibitor

Blocks the sodium-glucose cotransporter in the proximal tubule so glucose is excreted in urine rather than reabsorbed.

  • TypeSmall molecule
  • FormOral
  • Researched forLongevity
Join Skool for the protocol

No partner carries Canagliflozin yet.

The short version

  • Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
  • What the evidence isApproved for type 2 diabetes with major outcome trials behind it.
  • What to watchNausea, vomiting, belly pain and fast breathing even with normal glucose.

How Canagliflozin works

Canagliflozin blocks a transporter, and the transporter is in the kidney rather than anywhere metabolically interesting. Everything else this drug does is downstream of throwing sugar away.

The number that matters for a non-diabetic reader, and it is never stated. Filtered glucose load is glomerular filtration rate multiplied by plasma glucose. In someone with a normal fasting glucose the filtered load is roughly half that, and the fraction the drug can capture is smaller still.

Beyond glucose, the class produces genuine cardiovascular and renal outcome benefits that appear largely independent of the glucose lowering.

  • Oral

On the goal map: Glucose disposal, absorption & the post-meal curve (Metabolic health & insulin sensitivity)

Can you get Canagliflozin?

No partner sells it, and this page won’t pretend otherwise.

An SGLT2 inhibitor for type-2 diabetes. Needs a prescriber managing the diabetes, and none of my partners dispense it.

Research on Canagliflozin7 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Strong human outcome trials; rodent lifespan data (males).

Human clinical evidence

  • Approved for type 2 diabetes with major outcome trials behind it. CANVAS showed reduced major adverse cardiovascular events, and CREDENCE showed a significant reduction in kidney disease progression — a hard renal endpoint that changed practice.

  • CANVAS also found roughly a doubling of amputation risk, which led to a boxed warning that was later removed after further data. The signal was real in that trial and did not replicate; both facts belong in the record.

  • It also extended lifespan in male mice in the NIA Interventions Testing Program — again male-only, like acarbose and 17-alpha-estradiol.

Correlative data

  • Wide prescribing. The consistently reported issues are genital mycotic infections — a direct consequence of putting sugar in the urine — and volume depletion. Euglycemic diabetic ketoacidosis is rare, serious, and easy to miss because blood glucose looks normal.

How the mechanism reads

  • Inhibits SGLT2 in the proximal tubule, blocking glucose reabsorption so roughly 80 grams a day is excreted in urine. That is a genuinely novel mechanism — it lowers glucose independently of insulin entirely.

    Mechanistic
  • The cardiovascular and renal benefits are larger than glucose-lowering explains, and are thought to come from reduced intraglomerular pressure, a shift toward ketone metabolism in the heart, and plasma volume reduction.

    Mechanistic
  • And also behind the caution that it is not a weight drug and carries real infection and DKA risk.

    Mechanistic

Sources

  • Sharma A, et al. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 2024 · PMID 38240199
  • Chen AX, et al. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2024 · PMID 39036974
  • Snyder JM, et al. Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice. GeroScience 2023 · PMID 35974129
  • Wezeman J, et al. Sex Matters in Aging. The Canagliflozin Story. Aging Pathobiology and Therapeutics 2022 · PMID 36540066
  • Lakusic N, et al. Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors. World Journal of Cardiology 2022 · PMID 36339887
  • Guo G, et al. Physiologically based pharmacokinetic model of sodium-glucose cotransporter 2 inhibitors predicted pharmacokinetics and pharmacodynamics to explore dosage regimen for patients with type 2 diabetes mellitus and renal insufficiency. Frontiers in Pharmacology 2025 · PMID 40230691
  • Klen J, et al. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. International Journal of Molecular Sciences 2021 · PMID 34575958

Canagliflozin safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Type 1 diabetes or any past diabetic ketoacidosis.
  • Foot ulcers or peripheral artery disease, because the CANVAS program found more amputations.
  • Dehydration, low blood pressure or loop diuretic use.
  • Recurrent genital yeast infection or urinary infection.
  • Prolonged fasting or a ketogenic diet, which sets the stage for euglycemic ketoacidosis.

What’s expected

  • Glucose appears in urine and urination rises.
  • Small falls in weight and blood pressure.
  • Genital itching or yeast infection from glucose in urine.

Watch for

  • Nausea, vomiting, belly pain and fast breathing even with normal glucose.
  • A foot sore, toe pain or color change.
  • Genital pain, redness and fever, the Fournier's gangrene pattern.

Labs that tell you it’s working

  • HbA1c: the glucose effect of blocking renal glucose reabsorption.
  • Cystatin C with eGFR: an early dip in filtration is expected, with long-term kidney protection.
  • Urinalysis: glucose spill and any urinary infection.
  • Comprehensive Metabolic Panel: bicarbonate and sodium for acidosis and volume.

SGLT2 inhibition in the proximal tubule: urinary glucose loss, volume contraction and ketone shift drive its benefits and its hazards. PMID 36339887 PMID 39036974

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

Canagliflozin FAQ4 common questions

Is Canagliflozin approved for human use?
No. Canagliflozin is a research compound.
What is Canagliflozin researched for?
Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Which labs show whether it's doing anything?
HbA1c; Cystatin C with eGFR; Urinalysis; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Canagliflozin: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Canagliflozin is. Skool covers how it is run.

Free on this page

What Canagliflozin is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Canagliflozin is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Join Skool for the protocol